{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:35:47Z","timestamp":1789529747486,"version":"build-2803163510"},"reference-count":50,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gepirone, an antidepressant drug, is biotransformed into two principal metabolites [1\u2010(2\u2010pyrimidinyl)\u2010piperazine (1\u2010PP) and 3\u2032\u2010OH\u2010gepirone] primarily by CYP3A enzymes. Metabolism of gepirone in the presence of ketoconazole, a potent inhibitor of human CYP3A activity, was studied in vitro in human liver microsomes. The clinical pharmacokinetic interaction of ketoconazole (as a maximal chemical inhibitor of CYP3A isoforms) with single doses of gepirone was evaluated in a Phase 1 study in human volunteers (N = 24). In vitro coincubation of gepirone with increasing concentrations of ketoconazole produced extensive inhibition of 1\u2010PP and 3\u2032\u2010OH\u2010gepirone formation, with IC\n                    <jats:sub>50<\/jats:sub>\n                    values in the range of 0.026 \u00b5M to 0.162 \u00b5M. These inhibitory values are substantially lower than clinically encountered systemic concentrations of ketoconazole, thereby predicting extensive in vivo increases in gepirone exposure when coadministered with ketoconazole. In the clinical pharmacokinetic study, ketoconazole produced large increases in gepirone exposure by factors of 5.92\u2010 to 7.80\u2010fold. Appearance of 1\u2010PP in the systemic circulation decreased by factors of 0.56 to 0.97, while appearance of 3\u2032\u2010OH\u2010gepirone increased by 1.70\u2010 to 2.43\u2010fold. The clinical findings are consistent with the in vitro results, and underlie the labeling recommendation that gepirone not be coadministered with \u201cstrong\u201d CYP3A inhibitors.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70059","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T08:55:04Z","timestamp":1750323304000},"page":"1433-1442","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ketoconazole Inhibition of Gepirone Biotransformation and Clearance: In Vitro and Clinical Studies"],"prefix":"10.1002","volume":"65","author":[{"given":"Zhengzhe","family":"Yang","sequence":"first","affiliation":[{"name":"Program in Pharmacology and Drug Development Tufts University School of Medicine  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Amin","family":"Hossain","sequence":"additional","affiliation":[{"name":"Program in Pharmacology and Drug Development Tufts University School of Medicine  Boston MA USA"},{"name":"Department of Neurosurgery Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Program in Pharmacology and Drug Development Tufts University School of Medicine  Boston MA USA"},{"name":"University of Florida College of Pharmacy  Gainesville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Program in Pharmacology and Drug Development Tufts University School of Medicine  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Singleton","sequence":"additional","affiliation":[{"name":"Program in Pharmacology and Drug Development Tufts University School of Medicine  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Markowitz","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy  Gainesville FL USA"},{"name":"Center for Pharmacogenomics and Precision Medicine University of Florida  Gainesville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Greenblatt","sequence":"additional","affiliation":[{"name":"Program in Pharmacology and Drug Development Tufts University School of Medicine  Boston MA USA"},{"name":"Clinical and Translational Sciences Institute Tufts Medical Center and Tufts University School of Medicine  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(99)00003-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199006001-00003"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199401050-00009"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0071-0"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01014-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10421"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222120-00002"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600650804"},{"key":"e_1_2_9_10_1","first-page":"90","article-title":"Pharmacokinetics tricks and traps: flip\u2010flop models","volume":"1","author":"Boxenbaum H","year":"1998","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.11.19"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/87551225241269179"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01975-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb04715.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2003.09.012"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222080-00003"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874073100903010001"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050770"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.340"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000138199"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2019.55.7.2958474","article-title":"Gepirone hydrochloride: A novel antidepressant with 5\u2010HT1A agonistic properties","volume":"77","author":"Gill AK","year":"2019","journal-title":"Drugs of Today"},{"issue":"1","key":"e_1_2_9_22_1","first-page":"s68","article-title":"Effect of the 5\u2010HT1A agonist geprione HCl and its metabolite 3\u2019\u2010OH\u2010gepirone on the 5\u2010HT system in the rat brain","volume":"5","author":"Blier P","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"e_1_2_9_23_1","first-page":"s68","article-title":"The preclinical antidepressant\u2010like profile of the 5\u2010HT1A receptor agonist gepirone and its metabolite 3\u2019\u2010OH\u2010gepirone","volume":"5","author":"Ward NM","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038020-00002"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2010.01202.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12668"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.230"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0840-7_24"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12820"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2017.1370655"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002462"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.1c00049"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13079"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.732"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12644"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03545.x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90057-1"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2010.506224"},{"issue":"9","key":"e_1_2_9_39_1","first-page":"s208","article-title":"Pharmacokinetics (PH) and disposition of gepirone (GEP) and 1\u2010pyrimidinylpiperazine (1\u2010PP) in humans after intravenous (i.v.) and oral (p.o.) administration of 14 C\u2010gepirone","volume":"7","author":"Tay LK","year":"1990","journal-title":"Pharm Res"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6997(25)06653-0"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb04719.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.609"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1622"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.100"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.652"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.400"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.711"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.795"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.8.800"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.160-165.2002"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001198"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:43:42Z","timestamp":1761983022000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/jcph.70059"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70059","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"2025-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}